{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:50:17Z","timestamp":1790272217049,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Central Plains Scholars Workstation","award":["Grant number: 244400510021"],"award-info":[{"award-number":["Grant number: 244400510021"]}]},{"name":"Key Scientific Research Projects Plan of Colleges and Universities in Henan Province","award":["25A320034"],"award-info":[{"award-number":["25A320034"]}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"crossref","award":["CSTB2022NSCQ-MSX0846"],"award-info":[{"award-number":["CSTB2022NSCQ-MSX0846"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54052-8","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:13:55Z","timestamp":1779506035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Temperature-sensitive liquid embolic agent loaded with Lobaplatin in the TACE procedure for rabbit VX2 liver tumor"],"prefix":"10.1038","volume":"16","author":[{"given":"Yahua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangduan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"21","key":"54052_CR1","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.3390\/ijms21218165","volume":"21","author":"Y Chang","year":"2020","unstructured":"Chang, Y. et al. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int. J. Mol. Sci. 21(21), 8165 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"54052_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"54052_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","volume":"72","author":"J-L Raoul","year":"2019","unstructured":"Raoul, J.-L. et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat. Rev. 72, 28\u201336 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"54052_CR4","doi-asserted-by":"publisher","first-page":"1714314","DOI":"10.3389\/fimmu.2026.1714314","volume":"17","author":"J Li","year":"2026","unstructured":"Li, J. et al. Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk. Front. Immunol. 17, 1714314 (2026).","journal-title":"Front. Immunol."},{"issue":"5","key":"54052_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18(5), 293\u2013313 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"54052_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4329\/wjr.v9.i5.245","volume":"9","author":"G Greco","year":"2017","unstructured":"Greco, G. et al. Transarterial chemoembolization using 40 \u00b5m drug eluting beads for hepatocellular carcinoma. World J. Radiol. 9(5), 245\u2013252 (2017).","journal-title":"World J. Radiol."},{"issue":"4","key":"54052_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/life11040358","volume":"11","author":"SM Cho","year":"2021","unstructured":"Cho, S. M. et al. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20\u201340 \u00b5m and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm. Life 11(4), 358 (2021).","journal-title":"Life"},{"issue":"11","key":"54052_CR8","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1007\/s11547-025-02069-w","volume":"130","author":"F Giurazza","year":"2025","unstructured":"Giurazza, F. et al. Conventional vs. DEB vs. DSM: Which technique for palliative TACE in intermediate-stage HCC? Results on 70 patients in terms of efficacy and tolerance. Radiol. Med. 130(11), 1888\u20131896 (2025).","journal-title":"Radiol. Med."},{"key":"54052_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.actbio.2024.07.022","volume":"185","author":"D Shi","year":"2024","unstructured":"Shi, D. et al. Temperature-sensitive nanogels combined with polyphosphate and cisplatin for the enhancement of tumor artery embolization by coagulation activation. Acta Biomater. 185, 240\u2013253 (2024).","journal-title":"Acta Biomater."},{"issue":"10","key":"54052_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41419-019-1918-1","volume":"10","author":"D Li","year":"2019","unstructured":"Li, D. et al. Lobaplatin promotes (125)I-induced apoptosis and inhibition of proliferation in hepatocellular carcinoma by upregulating PERK-eIF2\u03b1-ATF4-CHOP pathway. Cell Death Dis. 10(10), 744 (2019).","journal-title":"Cell Death Dis."},{"key":"54052_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1756-8722-3-43","volume":"3","author":"Q Wu","year":"2010","unstructured":"Wu, Q. et al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. J. Hematol. Oncol. 3, 43 (2010).","journal-title":"J. Hematol. Oncol."},{"key":"54052_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000002154","author":"AU Kamran","year":"2015","unstructured":"Kamran, A. U. et al. Transcatheter arterial chemoembolization with gelatin sponge microparticles treated for BCLC stage B hepatocellular carcinoma. Medicine https:\/\/doi.org\/10.1097\/md.0000000000002154 (2015).","journal-title":"Medicine"},{"issue":"2","key":"54052_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4103\/jcrt.jcrt_2250_24","volume":"21","author":"S Zhou","year":"2025","unstructured":"Zhou, S. et al. An analysis of the clinical efficacy and safety of a temperature-sensitive liquid embolic agent loaded with lobaplatin for the treatment of unresectable primary hepatocellular carcinoma through chemoembolization. J. Cancer Res. Ther. 21(2), 504\u2013508 (2025).","journal-title":"J. Cancer Res. Ther."},{"key":"54052_CR14","doi-asserted-by":"publisher","first-page":"1153759","DOI":"10.3389\/fonc.2023.1153759","volume":"13","author":"K Ren","year":"2023","unstructured":"Ren, K. et al. Bevacizumab-loaded CalliSpheres beads: in vitro loading, release profiles and application in rabbit liver VX(2) tumor model. Front. Oncol. 13, 1153759 (2023).","journal-title":"Front. Oncol."},{"key":"54052_CR15","doi-asserted-by":"publisher","DOI":"10.1159\/000546697","author":"YR Kim","year":"2025","unstructured":"Kim, Y. R. et al. Updated network meta-analysis of first-line systemic treatments for advanced HCC: Consistent role of TACE. Liver Cancer https:\/\/doi.org\/10.1159\/000546697 (2025).","journal-title":"Liver Cancer"},{"key":"54052_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.114006","author":"Y Guo","year":"2025","unstructured":"Guo, Y. et al. Immunotherapy improved the efficacy of TACE or TACE plus MTTs in HCC patients: A meta-analysis. Int. Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2024.114006 (2025).","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"54052_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/14737140.2025.2489651","volume":"25","author":"QB Wang","year":"2025","unstructured":"Wang, Q. B. et al. The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cave and\/or right atrium: A systematic review and single-arm meta-analysis. Expert Rev. Anticancer Ther. 25(5), 561\u2013570 (2025).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"54052_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202502566","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Recent advances in embolic agents for transarterial chemoembolization of hepatocellular carcinoma. Adv. Healthc. Mater. https:\/\/doi.org\/10.1002\/adhm.202502566 (2025).","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"54052_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s13346-023-01425-5","volume":"14","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Application of temperature-sensitive liquid embolic agent loaded with oxaliplatin in the TACE procedure for rabbit VX2 gastric cancer. Drug Deliv. Transl. Res. 14(3), 705\u2013717 (2024).","journal-title":"Drug Deliv. Transl. Res."},{"issue":"29","key":"54052_CR20","doi-asserted-by":"publisher","first-page":"10835","DOI":"10.1039\/D2DT01875F","volume":"51","author":"S Alassadi","year":"2022","unstructured":"Alassadi, S., Pisani, M. J. & Wheate, N. J. A chemical perspective on the clinical use of Platinum-based anticancer drugs. Dalton Trans. 51(29), 10835\u201310846 (2022).","journal-title":"Dalton Trans."},{"key":"54052_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fphar.2020.00343","volume":"11","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front. Pharmacol. 11, 343 (2020).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54052-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:26:36Z","timestamp":1786487196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54052-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54052"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54052-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This animal study was approved by the Committee on the Ethics of Animal Experiments of the Second Affiliated Hospital of Chongqing Medical University\u2014approval number 2022-421. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent has been asked where appropriate.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24945"}}